Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals director Camille L. Bedrosian reported receiving new equity awards. She was granted 5,925 restricted stock units representing rights to receive Common Stock, vesting 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to continued board service.
She also received stock options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. After these awards, she directly holds 22,225 shares of Common Stock and 9,730 options.
Crinetics Pharmaceuticals director Wendell Wierenga received new equity awards in the form of stock and options. He was granted 5,925 shares of Common Stock as restricted stock units at no cost, bringing his direct holdings to 122,071 shares after the grant.
He also received a stock option covering 9,730 shares of Common Stock with an exercise price of $35.87 per share and an expiration date in 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to his continued service on the board.
Crinetics Pharmaceuticals director Stephanie Okey received new equity awards as board compensation. She was granted 5,925 restricted stock units representing future common shares and a stock option for 9,730 shares at an exercise price of $35.87 per share. The restricted stock units and option vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued board service. Following the grant, she holds 12,325 shares of common stock directly.
Crinetics Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held via live webcast on June 18, 2026. Holders of 102,030,415 shares of common stock were present virtually or by proxy, representing approximately 97% of the outstanding shares eligible to vote.
Stockholders elected three Class II directors—Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S.—to three-year terms expiring at the 2029 annual meeting. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
Crinetics Pharmaceuticals director Stephanie Okey reported selling a total of 6,900 shares of Common Stock in open-market transactions. The sales on June 17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan, at volume-weighted average prices of $35.62 and $36.22 per share.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported a series of estate and charitable planning moves involving gifts of 1,937,600 shares of common stock on May 29, 2026. The transactions are coded as bona fide gifts, with reported prices of $0.0000 per share, indicating no sale proceeds.
The gifts include transfers among multiple family trusts, a charitable remainder trust, and his spouse, with the filing noting that he disclaims beneficial ownership of certain trust-held shares except for his pecuniary interest. Following these transactions, he continues to hold significant positions, including 626,978 shares directly and 439,005 shares indirectly through Family Trust 1.
T. Rowe Price Associates, Inc. filed an amendment reporting beneficial ownership of 5,355,011 shares of Crinetics Pharmaceuticals common stock, representing 5.1% of the class. The filing lists sole voting power over 5,352,428 shares and sole dispositive power over 5,355,011 shares. The filing also includes a declarative statement denying beneficial ownership.
Wellington Management Group LLP amended its Schedule 13G/A to report 7.79% beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock. The filing lists shared voting power and shared dispositive power across related Wellington entities, including 8,157,204 shares of shared dispositive power as reported on cover pages.
Driehaus Capital Management LLC amends its Schedule 13G/A to report beneficial ownership of Crinetics Pharmaceuticals common stock. As of March 31, 2026, Driehaus held 6,395,922 shares, representing 6.11% of the class, down from 7.54% as of December 31, 2023. The filing states these shares are held on a fully discretionary basis for multiple clients and that voting and dispositive power is shared by Driehaus. The amendment was signed on May 15, 2026.